IMPDH2 and ovarian carcinoma: In addition, accumulated evidence has revealed the aberrantly high expression of IMPDH2 in many cancers, such as ovarian cancer,18 non‐small cell lung cancer,19 triple‐negative breast cancer,20 glioblastoma,15 kidney cancer,21 bladder cancer21 and colorectal cancer (CRC),22 implying that IMPDH2 is a potential therapeutic target for cancer.